Subscribe: Untitled
http://www.freepatentsonline.com/rssfeed/rssapp424.xml
Added By: Feedage Forager Feedage Grade C rated
Language: English
Tags:
antibody  compositions  comprising  invention relates  invention  methods  present invention  present  relates  thereof  treatment 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Untitled

Untitled





 



SYSTEMS AND METHODS FOR ANALYZING PERSISTENT HOMEOSTATIC PERTURBATIONS

Thu, 06 Apr 2017 08:00:00 EDT

This invention is in the field of homeostasis analysis. More particularly, it relates to systems and methods for analyzing persistent homeostatic perturbations, i.e. chronic stress, by measuring levels of biomarkers that are related to chronic stress. This invention is also directed to systems and methods for analyzing the molecular mechanisms of chronic stress.



Quantifying Met Protein for Cancer Treatment

Thu, 06 Apr 2017 08:00:00 EDT

Methods are provided for treating a gastric cancer patient. A specific Met fragment peptide is precisely quantitated by SRM-mass spectrometry directly in gastric tumor cells collected from gastric tumor tissue that was obtained from the cancer patient and compared to a reference level. If the Met peptide is below the reference level a second therapeutic regimen is used to treat the patient whereas if the Met peptide is above the reference level then a first therapeutic regimen combining, for example, the second regimen with one or more Met inhibitor therapeutic agents may be used to treat the patient.



Polymer Viral Compositions

Thu, 06 Apr 2017 08:00:00 EDT

There are provided, inter alia, viral compositions including a viral particle in contact with a polymer and the polymer is linked to a recognition moiety, and methods of use thereof.



IMMUNOGLOBULIN-BOUND EXTRACELLULAR VESICLES AND USES THEREOF

Thu, 06 Apr 2017 08:00:00 EDT

Provided are methods of isolating IgG-bound (e.g., IgG-bound or protein G-recognized IgG-bound) extracellular vesicles from a sample containing a biological fluid from a subject, where the IgG (e.g., IgG2 or protein G-recognized IgG) is bound to an antigen present on the surface of the extracellular vesicle and the IgG (e.g., IgG2 or protein G-recognized IgG) is an endogenous antibody. Also provided are methods of diagnosing a cancer in a subject that include detecting the presence of one or more tumor antigens in an isolated IgG-bound (e.g., IgG2-bound or protein G-recognized IgG-bound) extracellular vesicle, and methods of treating a subject that include administering one or more cancer therapeutics to a subject having an IgG-bound (e.g., IgG2-bound or protein G-recognized IgG-bound) extracellular vesicle that contains one or more tumor antigens.



DIAGNOSTIC REAGENTS

Thu, 06 Apr 2017 08:00:00 EDT

There is provided a diagnostic reagent useful to determine whether an animal has a tuberculosis infection or has been exposed to a tuberculosis agent, for example a Mycobacterium. The reagent is useful to distinguish between such an animal and an animal which has been vaccinated against a tuberculosis infection.



USE OF INTERLEUKIN-2 FOR DIAGNOSIS OF CELIAC DISEASE

Thu, 06 Apr 2017 08:00:00 EDT

Provided herein are methods of identifying a subject having or at risk for having Celiac disease by determining a level of IL-2 in a sample from a subject.



CROSSLINKED FIBERS AND METHOD OF MAKING SAME USING UV RADIATION

Thu, 06 Apr 2017 08:00:00 EDT

Cross-linked fibers include first and second precursors, each possessing a core and at least one functional group known to have click reactivity when exposed to UV radiation. Mixtures of the first and second precursors are extruded to produce a filament and irradiated with UV light during the extrusion process.



LENTIVIRAL VECTORS

Thu, 06 Apr 2017 08:00:00 EDT

This invention relates to lentiviral gene transfer vectors pseudotyped with hemagglutinin-neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, comprising a promoter and a transgene; and methods of making the same. The present invention also relates to the use of said vectors in gene therapy, particularly for the treatment of respiratory tract diseases such as Cystic Fibrosis (CF).



AAV VECTORS FOR RETINAL AND CNS GENE THERAPY

Thu, 06 Apr 2017 08:00:00 EDT

Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of rAAV particles. Further provided herein are improved recombinant adeno-associated virus (rAAV) (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of disorders of the CNS. The invention provides methods for delivering the rAAV to the CNS, methods for treating disorders of the CNS with improved compositions of rAAV particles, and kits for delivering the rAAV to the CNS and/or treating a CNS disorder.



BIOLOGICAL STATE MACHINES

Thu, 06 Apr 2017 08:00:00 EDT

Provided herein are recombinase-based frameworks for building state machines in vitro and in vivo by using chemically controlled DNA excision and inversion operations to encode state in DNA sequence.



COAGULATION FACTOR VII POLYPEPTIDES

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.



INFLUENZA M2 PROTEIN MUTANT VIRUSES AS LIVE INFLUENZA ATTENUATED VACCINES

Thu, 06 Apr 2017 08:00:00 EDT

A method to prepare recombinant influenza viruses comprising a mutant M2 protein which has a deletion of two or more residues in the cytoplasmic tail and is attenuated in vivo, is provided, as well the resulting virus and vaccines with the virus.



IBV STRAINS AND USES THEREOF

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to novel infectious bronchitis virus strains and the uses thereof. The invention particularly relates to an inactivated or attenuated IBV, as well as to vaccine compositions comprising the same and the uses thereof to vaccinate avians. The invention also relates to nucleic acids, infected cells and methods for detecting the infectious bronchitis virus strains of the invention in any sample.



METHODS AND COMPOUNDS FOR PHOTOTHERAPY WITH CHALCOGENORHODAMINE PHOTOSENSITIZERS

Thu, 06 Apr 2017 08:00:00 EDT

A method of selectively depleting pathogenic T lymphocytes from a blood cell composition is carried out by (a) combining the cell composition ex vivo with an active compound in an effective amount, and then (b) irradiating the cells with light ex vivo for a time and at an intensity sufficient to selectively kill pathogenic T lymphocytes in said cell composition. Chalcogenorhodamine photosensitizers useful as such active compounds are also described.



AMINOSILOXANE POLYMER AND METHOD OF FORMING

Thu, 06 Apr 2017 08:00:00 EDT

An aminosiloxane polymer includes at least one Si-bonded functional group. This functional group has the chemical formula: —(R—NH)aR1—N(R2)—CH(—COOH)(—R3—C(═O)—NR42) (I). In Formula (I), R is a C1-C10 hydrocarbon group. R1 is a C1-C10 hydrocarbon group. R2 is a hydrogen atom, a C1-C12 hydrocarbon group, or a phenyl group. R3 is a C1-C4 hydrocarbon group. Each R4 is independently a hydrogen atom, a C1-C12 hydrocarbon group, a C1-C12 hydroxyl-hydrocarbon group, or a phenyl group. Moreover, “a” is 0 or 1, such that (R—NH) is optional. The aminosiloxane polymer can be formed using the method of this disclosure and can be formed in, and/or included in, the emulsion of this disclosure.



Animal Models and Therapeutic Molecules

Thu, 06 Apr 2017 08:00:00 EDT

The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.



USE OF ANTIBODY CONJUGATES

Thu, 06 Apr 2017 08:00:00 EDT

Provided herein are methods for inducing growth arrest or apoptosis in cancer cells in a subject. Further provided are methods of inhibiting or treating metastasis of a cancer cell in a subject. The methods involve administering to the subject an antibody conjugate containing an antibody, variant thereof, or functional fragment thereof having binding specificity of the antibody as produced by the hybridoma having ATCC accession number PTA 2439 and a biologically active molecule. The antibody (e.g., mAb 3E10) variant or functional fragment thereof provides for the in vivo transduction of the conjugate to the nucleus of mammalian cells, where the conjugated biologically active molecule may exert its effect. In particular embodiments, the antibody conjugate comprises a single chain Fv fragment of an antibody having the binding specificity of mAb 3E10 produced by ATCC PTA 2439, conjugated to p53.



BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

Thu, 06 Apr 2017 08:00:00 EDT

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.



POLYPEPTIDE STRUCTURAL MOTIFS ASSOCIATED WITH CELL SIGNALING ACTIVITY

Thu, 06 Apr 2017 08:00:00 EDT

Isolated polypeptides comprising or consisting essentially of specific structural motifs (e.g., three β-sheets and two α-helices) are provided, wherein the polypeptides exhibit at least one cell signaling and/or other non-canonical activity of biological relevance. Also provided are polynucleotides encoding such polypeptides, binding agents that bind such polypeptides, analogs, variants and fragments of such polypeptides, etc., as well as compositions and methods of identifying and using any of the foregoing.



Anti Human Notch4 Antibody

Thu, 06 Apr 2017 08:00:00 EDT

The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.



DOSAGE AND ADMINISTRATION OF ANTI-IGF-1R, ANTI-ErbB3 BISPECIFIC ANTIBODIES, USES THEREOF AND METHODS OF TREATMENT THEREWITH

Thu, 06 Apr 2017 08:00:00 EDT

Provided herein are compositions comprising anti-IGF-1R, anti-ErbB3 bispecific antibodies alone or in combination with other anti-cancer agents. Also provided are methods of treating a subject having cancer and methods for determining whether a patient with cancer is likely to respond to the compositions described herein.



HUMAN ANTIBODIES TO HUMAN TNF-LIKE LIGAND 1A (TL1A)

Thu, 06 Apr 2017 08:00:00 EDT

A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1A antibodies are useful in treating diseases or disorders associated with TL1A, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation.



AMINO ACID SEQUENCES DIRECTED AGAINST RANK-L AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF BONE DISEASES AND DISORDERS

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.



ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOF

Thu, 06 Apr 2017 08:00:00 EDT

The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.



HUMAN ANTIBODIES TO GFR ALPHA3 AND METHODS OF USE THEREOF

Thu, 06 Apr 2017 08:00:00 EDT

The present invention provides antibodies that bind to human GFRα3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFRα3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFRα3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.



AGENTS INHIBITING GRANULIN FOR TREATMENT OF CANCER

Thu, 06 Apr 2017 08:00:00 EDT

The disclosure provides agents that inhibit granulin signalling for use as medicaments to reduce cancer stem cell activity in the treatment of cancer. The disclosure also provides agents that inhibit soluble granulin signalling for use in the treatment of cancer. The treatments of the disclosure may be of particular utility in breast cancer; prostate cancer; and melanoma, and are also of use in treatment of cancers associated with hypoxic tumours. Suitable agents may include those that inhibit granulin expression, inhibit granulin cleavage, or bind to and inhibit soluble granulin. Such agents may be used in combination with inhibitors of angiogenesis.



BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

Thu, 06 Apr 2017 08:00:00 EDT

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.



METHODS OF TREATING DISEASES WHICH ARE MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE CELLS

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.



Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to the identification of certain biomarkers for use in identifying patients who have, or are likely to develop an IL-33 mediated disease or disorder and who are more likely to respond to therapy with an IL-33 antagonist. The invention also relates to methods of treatment of an IL-33-mediated disease or disorder in a patient by administering an IL-33 antagonist to the patient in need thereof and monitoring the effectiveness of therapy using the biomarkers described herein. Also provided are methods for decreasing the level of at least one biomarker in a subject suffering from an IL-33-mediated disease or disorder, and methods for treating such diseases or disorders according to the expression levels of one or more biomarkers. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-33 antagonist.



SOLUBILITY OPTIMIZATION OF IMMUNOBINDERS

Thu, 06 Apr 2017 08:00:00 EDT

The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention.



SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening.



ANTIBODY VARIANTS

Thu, 06 Apr 2017 08:00:00 EDT

Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen.



OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES

Thu, 06 Apr 2017 08:00:00 EDT

The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.



THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to a therapeutic agent for inflammation in which histone is involved, the agent comprising a monoclonal antibody or an antigen binding fragment thereof which binds to a peptide consisting of an amino acid sequence represented by SSVLYGGPPSAA (SEQ ID NO:1) or a conjugate of the peptide and a pharmaceutically acceptable carrier.



ANTI-GP73 MONOCLONAL ANTIBODIES AND METHODS OF OBTAINING THE SAME

Thu, 06 Apr 2017 08:00:00 EDT

Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.



SINGLE DOMAIN BINDING MOLECULE

Thu, 06 Apr 2017 08:00:00 EDT

The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.



Antibodies that Neutralize Botulinum Neurotoxins

Thu, 06 Apr 2017 08:00:00 EDT

This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.



ALBUMIN FUSION PROTEINS

Thu, 06 Apr 2017 08:00:00 EDT

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.



SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TREATMENT OF MEDICAL DISORDERS

Thu, 06 Apr 2017 08:00:00 EDT

The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNFα by administering a TNFα antagonist, such as recombinant TNFR:Fc.



DUAL SPECIFIC BINDING PROTEINS HAVING A RECEPTOR SEQUENCE

Thu, 06 Apr 2017 08:00:00 EDT

Engineered multispecific binding proteins that bind at least one ligand for a receptor are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.



Peptide Analogs for Treating Diseases and Disorders

Thu, 06 Apr 2017 08:00:00 EDT

Provided herein are peptides, that in combination with metformin, are effective for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.



HOMOGENEOUS PREPARATIONS OF IL-31

Thu, 06 Apr 2017 08:00:00 EDT

Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.



Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.



CYAA-BASED CHIMERIC PROTEINS COMPRISING A HETEROLOGOUS POLYPEPTIDE AND THEIR USES IN THE INDUCTION OF IMMUNE RESPONSES

Thu, 06 Apr 2017 08:00:00 EDT

The invention relates to a chimeric protein comprising or consisting of, from N-terminal to C-terminal, (a) a N-terminal part of a Bordetella CyaA protein (b) a heterologous polypeptide, and (c) a C-terminal part of a Bordetella CyaA protein. The invention also relates to a polynucleotide encoding a deleted version of a Bordetella CyaA, as well as a polynucleotide encoding this chimeric protein. A composition comprising at least one chimeric protein(s) of the invention and the prophylactic and/or therapeutic uses of said composition are also part of the invention.



IMMUNOGENIC HPV L2-CONTAINING VLPS AND RELATED COMPOSITIONS, CONSTRUCTS, AND THERAPEUTIC METHODS

Thu, 06 Apr 2017 08:00:00 EDT

The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.



METHODS AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS SPIKE PROTEINS

Thu, 06 Apr 2017 08:00:00 EDT

The present invention provides compositions and methods comprising a chimeric coronavirus spike protein.



MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF

Thu, 06 Apr 2017 08:00:00 EDT

Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.



2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use

Thu, 06 Apr 2017 08:00:00 EDT

The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.



FLUORINATED 2-AMINO-4-(BENZYLAMINO)PHENYLCARBAMATE DERIVATIVES

Thu, 06 Apr 2017 08:00:00 EDT

The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described.



USE OF VANILLIN DERIVATIVES AS PRESERVING AGENTS, PRESERVING PROCESS, COMPOUNDS AND COMPOSITION

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to the use, in a cosmetic, dermatological or pharmaceutical composition, of at least one compound of formula (I): in which: R2 represents a hydrogen atom or a methyl or ethyl radical;R3 represents a linear C1-C12 alkyl radical, optionally substituted with a hydroxyl group; or a linear C2-C12 alkenyl radical, optionally substituted with a hydroxyl group; as a preserving agent. The invention also relates to certain novel compounds and to the cosmetic, dermatological or pharmaceutical compositions comprising them.



ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING

Thu, 06 Apr 2017 08:00:00 EDT

An antibiotic-eluting article for implantation into a mammalian subject, produced by an additive manufacturing process wherein a polymeric material is concurrently deposited with a selected antibiotic. The additive manufacturing process may be a selective laser sintering process or a selective laser melting process or a selective heat sintering process or an electron beam melting process. The antibiotic-eluting article may be temporary or permanent orthopaedic skeletal component, an orthopaedic articulating joint replacement component, and/or an external hard-shell casing for an implantable device. One or more bone-growth-promoting compositions may be concurrently deposited with the polymeric material. The implantable device may be a cardiac pacemaker, a spinal cord stimulator, a neurostimulation system, an intrathecal drug pump for delivery of medicants into the spinal fluid, and infusion pump for delivery of chemotherapeutics and/or anti-spasmodics, an insulin pump, an osmotic pump, and a heparin pump.



CELL STRUCTURE FOR BRAIN DAMAGE TREATMENT, PRODUCTION METHOD THEREOF, AND BRAIN DAMAGE TREATMENT AGENT

Thu, 06 Apr 2017 08:00:00 EDT

An object of the present invention is to provide a cell structure for brain damage treatment which does not contain glutaraldehyde and in which it is possible to exhibit a sufficient effect of treating brain damage, a production method thereof, and a brain damage treatment agent. According to the present invention, there is provided a cell structure for brain damage treatment which contains biocompatible macromolecular blocks and at least one kind of cell and in which a plurality of the biocompatible macromolecular blocks are disposed in gaps between a plurality of the cells, in which the tap density of the biocompatible macromolecular block is 10 mg/cm3 to 500 mg/cm3 or a value obtained by dividing a square root of a cross-sectional area in a two-dimensional cross-sectional image of the biocompatible macromolecular block by a peripheral length is 0.01 to 0.13.



Phospholipid Reduction in Biological Tissue

Thu, 06 Apr 2017 08:00:00 EDT

A method of reducing phospholipid concentration in biological tissue. The biological tissue is immersed in an isopropyl alcohol solution for an effective period of time. After the effective period of time, the biological tissue has a phospholipid concentration that is at least 10 percent by weight less than an initial phospholipid concentration of the biological tissue.



Compositions For An Injectable, In Situ Forming Neuroscaffold And Methods Of Using The Same

Thu, 06 Apr 2017 08:00:00 EDT

Disclosed are injectable, biodegradable neuroscaffolds formed in situ by self-assembling biodegradable polymeric microparticles, nanoparticles, or any combination thereof, via copper-free click chemistry or Michael-type addition coupling reactions. The injectable, biodegradable neuroscaffolds provide 3-D structural support, neuroprotection, and/or subsequent regeneration in a subject with a spinal cord injury or a focal neurological disorder.



BIORESORBABLE METAL ALLOY AND IMPLANTS

Thu, 06 Apr 2017 08:00:00 EDT

Embodiments of the present disclosure provide for structures including an alloy of calcium, strontium, and magnesium.



WOUND DRESSING

Thu, 06 Apr 2017 08:00:00 EDT

This invention relates to a wound dressing, particularly to a stimuli responsive wound dressing comprising a lyophilized hyaluronic acid (HA) hydrogel, and a plurality of devices embedded within said lyophilized hyaluronic acid hydrogel. Each of the plurality of devices including chitosan and hypromellose and may be formed as biofilms and/or electrospun fiber mats.



BISPECIFIC PEPTIDE CONJUGATE AND RADIOACTIVE BISPECIFIC PEPTIDE IMAGING AGENT

Thu, 06 Apr 2017 08:00:00 EDT

Disclosed herein is a bispecific peptide conjugate comprising an epidermal growth factor receptor (EGFR) targeting peptide, an avβ3 integrin targeting peptide, and a linker, where the linker is conjugated respectively to the EGFR targeting peptide and the avβ3 integrin targeting peptide.



TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS

Thu, 06 Apr 2017 08:00:00 EDT

The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.



COMPOSITION FOR TARGET SUBSTANCE DETECTION COMPRISING MAGNETIC NANOPARTICLE HAVING A CURIE TEMPERATURE WHICH IS WITHIN BIOCOMPATIBLE TEMPERATURE RANGE AND SYSTEM FOR TARGET SUBSTANCE DETECTION

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to a composition for target substance detection using a magnetic nanoparticle having a Curie temperature which is within a biocompatible temperature range, a target substance detection system, and a method for obtaining an image of a living body or specimen. As the magnetic nanoparticle of the present invention has a Curie temperature within the temperature range of 0° C. to 41° C., the ferromagnetic and paramagnetic properties of the magnetic nanoparticle may be controlled within a biocompatible temperature range at a temperature at which a biological control agent is not destroyed, and the temperature of the magnetic nanoparticle is adjusted to control the magnetic properties thereof such that the properties of the magnetic nanoparticle may be used only when ferromagnetic properties are required, such as in the case of signal amplification in detecting, separating, and delivering biological control agents. Accordingly, the present invention can provide a biological substance detection system which satisfies both a decrease in non-specific binding and signal amplification using a magnetic nanoparticle having a Curie temperature which is within a biocompatible temperature range, and can be reused after detection.



NONINVASIVE IMAGING OF FOCAL ATHEROSCLEROTIC LESIONS USING FLUORESCENCE MOLECULAR TOMOGRAPHY

Thu, 06 Apr 2017 08:00:00 EDT

The present disclosure provides compositions comprising an oligopeptide comprising a fragment of a natriuretic peptide, wherein the fragment comprises the sequence Arg-Ile-Asp-Arg-Ile (SEQ ID NO:1), and a detectable label. Further disclosed are methods of imaging atherosclerotic plaque by optical imaging using a peptide composition.



COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP

Thu, 06 Apr 2017 08:00:00 EDT

Provided are methods of use of compounds comprising a self-immolative group, which compounds may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.



COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND OTHER PATHWAYS

Thu, 06 Apr 2017 08:00:00 EDT

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a molecularly targeted agent; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (VH), which includes an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7; and (ii) a light chain variable region (VL), which includes an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.



Methods of Treating Cancer Using Compositions of Antibodies and Carrier Proteins with Antibody Pretreatment

Thu, 06 Apr 2017 08:00:00 EDT

Described herein are methods, formulations and kits for treating a patient with cancer with anti-VEGF antibodies and albumin-bound chemotherapeutic/anti-VEGF antibody nanoparticle complexes.



METHODS AND COMPOSITIONS FOR TREATING ALLERGY AND INFLAMMATORY DISEASES

Thu, 06 Apr 2017 08:00:00 EDT

Described herein are therapeutic approaches with immune modifiers of the Th2 pathway for the treatment of allergic and inflammatory diseases. Aspects of the disclosure relate to methods for decreasing Th2-type cell responses in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an anti-Dectin-1 antibody or antigen binding fragment thereof operatively linked to a TLR agonist.



METHODS FOR MAKING CONJUGATES FROM DISULFIDE-CONTAINING PROTEINS

Thu, 06 Apr 2017 08:00:00 EDT

The invention provides methods to prepare protein conjugates from proteins having at least four accessible cysteine residues. In one embodiment, an antibody with four reducible disulfide linkages is reduced to provide four pairs of free cysteines. Each pair of free cysteines is reacted with a 1,3-dihaloacetone or similar reactant, linking the sulfur atoms of each pair together though a 3-carbon tether with a reactive ketone. A pair of these reactive ketones are linked together with and used to attach a single payload molecule, thus conjugating the antibody to two payload groups. This method gives a stabilized antibody conjugate with high selectivity for a ratio of two payloads per antibody.



Therapeutic Combinations Comprising Anti-FOLR1 Immunoconjugates

Thu, 06 Apr 2017 08:00:00 EDT

Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.



PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE

Thu, 06 Apr 2017 08:00:00 EDT

The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.



TREATING BLADDER TUMOR CELLS USING FIBRONECTIN ATTACHMENT PROTEIN AS A TARGET

Thu, 06 Apr 2017 08:00:00 EDT

Composition and methods are disclosed for utilizing microaggregation of FAP-containing complexes to promote their fast internalization. This approach allows the uptake of cytotoxic cargo coupled to either FAP-Antibodies or FAP-liposome complexes by tumor bladder cells. Importantly, this approach is efficient even under serum-free conditions such as the ones found in the lumen of the bladder.



Compositions and Methods for Enhancing Transport Through Mucus

Thu, 06 Apr 2017 08:00:00 EDT

The invention generally relates to compositions and methods for transporting substances across mucosal barriers. The invention also relates to methods of making and using such substances.



CHEMICALLY MODIFIED SMALL MOLECULES

Thu, 06 Apr 2017 08:00:00 EDT

Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.



N-ACETYLGLUCOSAMINE SUGAR CHAIN GROUP-CONTAINING COMPOUND, CARRIER COMPOUND FOR DRUG DELIVERY, DRUG PREPARATION, AND DRUG DELIVERY SYSTEM

Thu, 06 Apr 2017 08:00:00 EDT

An N-acetylglucosamine sugar chain group-containing compound which can easily reach cells/sites on which a vimentin and/or desmin protein(s) is/are exposed, which compound has excellent affinity to N-acetylglucosamine sugar chain-recognizing proteins; a drug delivery carrier compound comprising the compound: a preparation using the drug delivery earner compound; and a drug delivery system; are provided. These are an N-acetylglucosamine sugar chain group-containing compound having a weight average molecular weight within the range of 15,000 to 100,000; a drug delivery carrier compound comprising the compound; a preparation using the drug delivery carrier compound; and a drug delivery system.



MUCOSAL DELIVERY OF THERAPEUTIC MOLECULES, PROTEINS, OR PARTICLES COUPLED TO CERAMIDE LIPIDS

Thu, 06 Apr 2017 08:00:00 EDT

Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).



ANTI-NUCLEOLIN AGENT-CONJUGATED NANOPARTICLES

Thu, 06 Apr 2017 08:00:00 EDT

A composition comprises an anti-nucleolin agent conjugated to nanoparticles. The nanoparticles are non-magnetic, not iron oxide and not polyacrylamide. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier.



METHOD FOR STABILIZATION AND DELIVERY OF THERAPEUTIC MOLECULES

Thu, 06 Apr 2017 08:00:00 EDT

A method of treatment is disclosed, comprising administering a composition of Cyclodextrin and reduced, nanonized L-Glutathione to a patient in need of treatment, wherein the L-Glutathione molecule is non-acetylated, non-Esterified, and non-fatty acid attached.



ANTIBODY FORMULATION

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to pharmaceutical formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody. Such formulations comprise, in addition to the antigen binding protein, a buffering agent and a tonicity agent.



AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION PROCESS

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, pharmaceutical compositions comprising the conjugates, methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the conjugates for the same, and uses of the conjugates in the manufacture of medicaments for the same.



METHOD OF OBTAINING A POLYEPITOPIC PROTEIN AS WELL AS A DNA VECTOR FOR EMBODYING THIS METHOD

Thu, 06 Apr 2017 08:00:00 EDT

We disclose a method of obtaining a polyepitopic protein, a DNA vector for the embodiment of the method as well as polyepitopic proteins fused with macromolecular carriers. The proteins obtained according to the present invention are in a number of uses, in particular when used in the production of improved vaccines.



MICROORGANISMS FOR THERAPY

Thu, 06 Apr 2017 08:00:00 EDT

Therapeutic methods and vaccinia virus therefor are provided. The viruses are designed so that they accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms. Combinations of the viruses and anti-cancer agents and uses thereof for treating cancer also are provided.



REPLICATION-COMPETENT VSV-HIV ENV VACCINES

Thu, 06 Apr 2017 08:00:00 EDT

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.



INFLUENZA VIRUS REASSORTMENT

Thu, 06 Apr 2017 08:00:00 EDT

New influenza donor strains for the production of reassortant influenza A viruses are provided.



BACTERIAL VACCINE COMPONENTS AND USES THEREOF

Thu, 06 Apr 2017 08:00:00 EDT

Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.



MALARIAL ANTIGENS DERIVED FROM SUBTILISIN-LIKE PROTEASE 2 AND VACCINES AND METHODS OF USE

Thu, 06 Apr 2017 08:00:00 EDT

The present invention provides immunogenic compositions comprising one or more subtilisin-like protease 2 antigens, functional fragments or homologs thereof, from various Plasmodium species, methods, vectors comprising the antigens, and methods of use for the treatment of malaria and related disease.



INHIBITION OF TUMOR ANGIOGENESIS BY CHECKPOINT INHIBITORS AND ACTIVE VACCINATION

Thu, 06 Apr 2017 08:00:00 EDT

Disclosed are compositions of matter, methods, and protocols useful for treatment of cancer through induction of anti-angiogenic immune responses by vaccination together with immune modulation triggered by checkpoint inhibitors. The invention provides placenta, placental endothelial, placental fibroblasts, and mixtures thereof as immunogens, whose anti-angiogenic activity is augmented by utilization of checkpoint inhibitors. Means of differentiating tumor cells directly into endothelial or endothelial-like cells and utilizing said cells as immunogens for the purpose of inducing immunity against blood vessels feeding tumors. In one embodiment CTLA4 blockade is performed in combination with an immunogen capable of triggering immunity towards tumor endothelial cells. In another embodiment blockade of the PD1-PD1 ligand pathway is performed in combination with induction of anti-angiogenic immune response.



NANOPARTICLE COMPOSITIONS FOR SUSTAINED THERAPY

Thu, 06 Apr 2017 08:00:00 EDT

This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of TR1 cells and/or B cells in an antigen-specific manner and treating diseases and disorders in a subject in need thereof.



METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS

Thu, 06 Apr 2017 08:00:00 EDT

Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.



Reduction of Lipoma Tissue

Thu, 06 Apr 2017 08:00:00 EDT

The amount of adipose tissue, including lipomas, at selected locations in the body is reduced by introducing collagenase or collagenase plus another proteinase into the tissue.



NOVEL COMPOSITIONS FOR THE TREATMENT OF CANCER

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to novel compositions comprising proteolytic enzymes and fining agents as well as methods for the treatment and/or prevention of cancer using these compositions.



Composition for Prevention and Treatment of Joint Pain and the Method of Preparation Thereof

Thu, 06 Apr 2017 08:00:00 EDT

The present invention discloses a herbal composition for prevention and treatment of joint pain, the method of preparation thereof, and its application thereof. The composition relieves osteoarthritis pain and substantially treats osteoarthritis. It can be used for the prevention and treatment of osteoarthritis of various joints, including the knee joint, hip joint, wrist joint, spine joint, shoulder joint, and ankle joint. The composition disclosed herein can be formulated into tablet, capsule, dispersible tablet, chewable tablet, effervescent tablet, and buccal tablet. The composition comprises a mixture of glucosamine sulfate 2KCl, chondroitin sulfate, methyl-sulfonyl-methane (MSM), and any one or a combination of Sambucus williamsii Hance extract and Drynaria fortunei (Kunze) J. Sm. extract. Further, the mixture may comprise any one or a combination of type II collagen, Morinda officinalis root extract, Epimedium grandiflorum extract, and turmeric root extract. Preferably, the mixture is sieved and formulated into a dosage form with 0.10 g to 1.50 g of the mixture per dose. As compared to the prior art, the present invention offers advantages such as simple processing method, explicit functional components, and minimal side effects.



ADENO-ASSOCIATED VIRUS FACTOR VIII VECTORS

Thu, 06 Apr 2017 08:00:00 EDT

The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.



METHODS FOR TREATMENT OF CD14-MEDIATED DISORDERS AND RESPONSES

Thu, 06 Apr 2017 08:00:00 EDT

A method for blocking, inhibiting and/or decreasing cluster of differentiation 14 (CD14) function, CD14-mediated cellular response and/or treating CD14-mediated pathological conditions is disclosed. The method comprises administering to a subject in need thereof a pharmaceutical composition comprising: (a) a therapeutically effective amount of a recombinant protein comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 1, wherein the recombinant protein does not comprises a lectin-like domain 1 of a human thrombomodulin; and (b) a pharmaceutically acceptable vehicle, carrier, diluent, excipients, and/or salt.



METHODS AND COMPOSITIONS FOR MANAGING REPRODUCTION

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to methods, compositions and kits for controlling, managing or manipulating the non-human mammalian female reproductive cycle. The methods include oestrus induction and/or synchronisation, induction of ovulation and/or superovulation and optionally further includes a method of providing an immunopermissive uterine environment prior to insemination or implantation of embryos.



COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING RADIATION- OR CHEMOTHERAPY-INDUCED PULMONARY DYSFUNCTION

Thu, 06 Apr 2017 08:00:00 EDT

Compositions comprising one or more cytokines and methods for their use in inhibiting and/or alleviating effects of radiation therapy and/or chemotherapy and/or acute radiation syndrome in a subject in need thereof are provided.



COMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINS

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.



COMPOSITIONS COMPRISING COMPLEXES OF PROANTHOCYANIDINS WITH PEA PROTEINS

Thu, 06 Apr 2017 08:00:00 EDT

Disclosed is a complex of pea protein and proanthocyanidins for use in the treatment of disorders caused by alterations of the intestinal epithelial tissue.



METHODS FOR MODULATING CANCER CELLS AND STEM CELLS

Thu, 06 Apr 2017 08:00:00 EDT

The present invention provides methods for modulating pluripotency of stem cells and proliferation of cancer cells. The modulation is achieved by promoting dephosphorylation of mRNA-binding protein 3 (RBM3) and down-regulating expression or cellular level of pluripotency factor LIN28. Related methods are provided in the invention for promoting differentiation of stem cells and for inhibiting growth of tumors in subjects. The therapeutic methods of the invention typically entail contacting with a target cell (e.g., a tumor cell) or administering to a subject harboring the target cell a calpain inhibitor and/or an IGF1R inhibitor. Some methods of the invention employ both a calpain inhibitor and an IGF 1R inhibitor.



LOW FREQUENCY GLATIRAMER ACETATE THERAPY

Thu, 06 Apr 2017 08:00:00 EDT

A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.



Compositions Containing Extracts of Curcuma SPP and Zingiber officinale Which Are Useful to Reduce Peripheral Inflammation and Pain

Thu, 06 Apr 2017 08:00:00 EDT

Disclosed are compositions containing an extract of Curcuma spp, optionally as curcumin in the form of a complex with phospholipids, and a lipophilic extract of Zingiber officinale, for use in the treatment of osteoarthritis.



A composition for preventing, treating, and improving of voiding dysfunction comprising extract of Piper longum L.

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to a pharmaceutical composition for preventing or treating voiding dysfunction and a health functional food for preventing or improving of voiding dysfunction, comprising extract of Piper Longum L. as an active ingredient. The extract of Piper Longum L. according to the present invention is not only harmless, but also has outstanding effects of preventing, treating and improving voiding dysfunction by being involved in various mechanisms related to voiding dysfunction simultaneously so that it may increase a micturition interval, decrease a micturition pressure, increase a bladder capacity, inhibit detrusor contraction and induce relaxation of detrusor.



DIETARY SUPPLEMENTS AND METHODS FOR TREATING PAIN AND INFLAMMATION

Thu, 06 Apr 2017 08:00:00 EDT

The document provides compositions such as dietary supplements. Such compositions can be used to reduce pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis. The document also provides methods for reducing pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis.



Microbiomarker for Celiac Disease and a Related Product

Thu, 06 Apr 2017 08:00:00 EDT

The present invention relates to the field of medicine and in particular to celiac disease (CD). Specifically the present invention relates to methods and means for detection of CD using novel microbiomarker, celiac gut index (CGI). The invention relates also to methods and means for treatment or prophylaxis of CD. The present invention provides a novel product comprising a gut microbiome altering agent that, when administered to an individual, improves the state of health of individuals suffering or susceptible to suffer from celiac disease and possibly reduces the likelihood of acquiring celiac disease. The product of the invention provides a natural and safe manner for the treatment of celiac disease. The present invention provides also a novel method for aiding diagnosis of CD by the specific gut health biomarker, Celiac Gut Index (GCI). In the method a probability of a subject having celiac disease is determined by measuring the relative abundances of one or more microbial taxa in a fecal sample from a subject; and the probability of the subject having CD is determined based on the measured abundances as celiac gut index (CGI).